ML-004 for Autism Spectrum Disorder

ML-004 for Autism Spectrum Disorder
42%31%20%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 35.0%May 28 • YES 26.2%
MapLight Therapeutics ($MPLT)
No stock close$30.30$28.14$25.98May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • MPLT $26.50May 19 • MPLT $27.08May 20 • MPLT $27.81May 21 • MPLT $29.28May 22 • MPLT $28.75May 26 • MPLT $29.46May 27 • MPLT $29.55May 28 • MPLT $29.78

Will this trial show a positive result on change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain Score?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
3/10/26
Study Completion
4/17/26
Sponsor
MapLight Therapeutics
Ticker
$MPLT
Type
Phase 2
Trial Status
Completed
Trial Size
168
NCT
NCT05081245
Trial Description
This Phase 2 trial tested ML-004 in adolescents and adults with autism, measuring social communication change by Day 110.